{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Dutertre Martin"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-ECPF-GEOD-53474"],"project":["EurocanPlatform"],"abstract":["Alternative 3’-terminal exons, which use intronic polyadenylation sites, are generally unconserved and lowly expressed, while the main gene products end in the last exon of genes. In this study, we discover a class of human genes, where the last exon appeared recently during evolution, and the major gene product uses an alternative 3’-terminal exon corresponding to the ancestral last exon of the gene. This novel class of alternative 3’-terminal exons are down-regulated on a large scale by doxorubicin, a cytostatic drug targeting topoisomerase II, and play a role in cell cycle regulation, including centromere-kinetochore assembly. The RNA-binding protein, HuR/ELAVL1 is a major regulator of this specific set of alternative 3’-terminal exons. HuR binding to the alternative 3’-terminal exon in"],"repository":["biostudies-other"],"experiment_type":["transcription profiling by array"],"data_source":["EurocanPlatform"],"pubmed_authors":["Combe Emmanuel","Polay Espinoza Micaela","Dutertre Martin","Zahra Chakrama Fatima","Desmet François-Olivier","Mortada Hussein","Gratadou Lise","Auboeuf Didier"],"additional_accession":[]},"is_claimable":false,"name":"A novel class of alternative 3?-terminal exons is involved in cell-cycle regulation by topoisomerase inhibitors","description":"Alternative 3’-terminal exons, which use intronic polyadenylation sites, are generally unconserved and lowly expressed, while the main gene products end in the last exon of genes. In this study, we discover a class of human genes, where the last exon appeared recently during evolution, and the major gene product uses an alternative 3’-terminal exon corresponding to the ancestral last exon of the gene. This novel class of alternative 3’-terminal exons are down-regulated on a large scale by doxorubicin, a cytostatic drug targeting topoisomerase II, and play a role in cell cycle regulation, including centromere-kinetochore assembly. The RNA-binding protein, HuR/ELAVL1 is a major regulator of this specific set of alternative 3’-terminal exons. HuR binding to the alternative 3’-terminal exon in","dates":{"release":"2016-04-14T14:33:26Z","modification":"2016-04-14T14:33:26Z","creation":"2016-04-14T14:33:26Z"},"accession":"S-ECPF-GEOD-53474","cross_references":{"GEO":["GSE53474"],"ArrayExpress":["E-GEOD-53474"],"EFO":["EFO_0000305","EFO_0000322"],"ArrayExpress files":["E-GEOD-53474"]}}